57. STUDY ON THE CHANGE OF THE PERIPHERAL WHITE BLOOD COUNTS IN PATIENTS WITH HEPATITIS B VIRUS-RELATED CHRONI LIVER DISEASES
Main Article Content
Abstract
Objective: Liver cancer (LC) represents a significant global health burden, characterized by poor prognosis and requiring substantial efforts for effective control and improved outcomes. This study aimed to evaluate changes in peripheral blood white blood cell counts (WBC) among patients with chronic liver diseases (CLD) having hepatitis B virus (HBV) infection.
Methods: A cross-sectional descriptive study was conducted, analyzing data from 100 patients with HBV-related primary hepatocellular carcinoma (HCC), 25 patients with HBV-related cirrhosis (HBC), 25 patients with chronic hepatitis B (CHB), and 50 healthy controls (HC).
Results: WBC counts decreased progressively from the HC group to the CHB and HBC groups. Notably, WBC counts were significantly lower in HBC patients, compared to healthy controls (p < 0.05). In contrast, WBC counts were elevated in HCC patients relative to both the HBC group and the combined (HBC + CHB) group (p < 0.01). WBC count demonstrated the ability to distinguish HCC from HBC and the (HBC + CHB) group, with respective AUC values of 0.6934 (p = 0.0028) and 0.65 (p = 0.0028). At the optimal cutoff value (WBC > 4.945), WBC count showed high sensitivity in diagnosing HCC among chronically HBV-infected individuals, with a sensitivity of 87.9% and a low specificity of 41.20%.
Conclusion: WBC counts were reduced in HBC patients but increased in HCC patients, suggesting that elevated WBC may serve as a potential indicator of malignant transformation. WBC count showed discriminatory power in identifying HCC among patients with other CLD, such as CHB and the combined CHB + HBC group, with high sensitivity. As a readily accessible, non-invasive, and cost-free parameter, WBC may be a useful tool for HCC screening in patients with HBV-related cirrhosis.
Article Details
Keywords
Hepatocellular carcinoma HCC, hepatitis B virus, chronic liver disease, chronic hepatitis, liver cirrhosis, white blood count
References
[2] Patel A, Dossaji Z, Gupta K, Roma K, Chandler T-M, Minacapelli CD, et al. The Epidemiology, Transmission, Genotypes, Replication, Serologic and Nucleic Acid Testing, Immunotolerance, and Reactivation of Hepatitis B Virus. Gastro Hep Advances. 2024;3(2):139-50.
[3] Cheng JY, Shan GY, Wan H, Liu YY, Zhang YX, Shi WN, et al. Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances. World J Hepatol. 2024;16(12):1515-23.
[4] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
[5] Lee JG, Kang CM, Park JS, Kim KS, Yoon DS, Choi JS, et al. The actual five-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med J. 2006;47(1):105-12.
[6] Miller K, Barman P, Kappus M. Palliative care and end of life care in decompensated cirrhosis. Clin Liver Dis (Hoboken). 2023;22(1):10-3.
[7] Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol. 2019;25(27):3527-37.
[8] Zhou RR, Song YH, Xu CY, Zhang YY, Wu XW, Zhang L, et al. Altered counts and mitochondrial mass of peripheral blood leucocytes in patients with chronic hepatitis B virus infection. J Cell Mol Med. 2024;28(12):e18440.